Paradigm Global Events is proud to present Biosimilars and Follow-On Biologics Americas 2013.
Biosmilars drugs are, in essence, the biological equivalent of generics for the biopharmaceutical sector. The issues with generic drugs are well known as they have been on the market for a number of years. However, biosimilars are only recently coming on the market as patents for the original innovator drug expires.
There are a number of challenges with biosimilar drugs: commercial, regulatory, and technical. This conference examines all of them in turn and discusses for example: the current usage of biosimilars; what the commercial impact of them is; and what is happening in the BRIC countries.